| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 19th July 2019 | Dmitry Genkin | 93,390 | Grant/award etc. | $0.00 | |
| 14th March 2018 | Dmitry Genkin | 29,452 | Other acquisition or disposition | $0.00 |
Xenetic Biosciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's tumor cells.
Ticker: XBIO
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1534525
Employees: 4
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Xenetic Biosciences (XBIO) Investor Presentation - Slideshow
20th January 2021
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
